Skip to main content
Growth HormoneGHRH analog (secretagogue)

Sermorelin

Also known as: Sermorelin Acetate, GHRH(1–29)-amide, Geref, Sermorelin acetate

By the Peptide Dossier Editorial TeamUpdated How we source

Sermorelin is the active GHRH (1–29) fragment with a historical Geref diagnostic and pediatric-treatment record. Adult hormone responses and selected functional findings do not establish broad anti-aging, fat-loss or muscle-mass benefits.

Quick Facts

Class:GHRH analog (secretagogue)
US product context:Historical Geref approvals discontinued/withdrawn; no currently marketed FDA-approved sermorelin product identified.
Evidence context:Historical diagnostic/pediatric evidence and small adult physiology studies; class findings from tesamorelin must remain attributed to tesamorelin.

Identity, mechanism and pharmacokinetics

Sermorelin is synthetic GHRH (1–29)-amide, the shortest fully active portion of the hypothalamic signal that stimulates anterior-pituitary GH secretion. It requires a responsive pituitary, unlike exogenous HGH, which supplies the hormone directly. Endogenous feedback through somatostatin can reduce the signal, but no head-to-head trial establishes a general safety advantage over HGH.

GH stimulates hepatic IGF-1 production. Sermorelin is shorter-acting than CJC-1295 but uses the same GHRH pathway. A ten-man IV study measured a 4.3-minute disappearance half-time; its D-Ala2 comparator was not CJC-1295. That IV result is not a subcutaneous administration interval.

Sources: [2], [19]

Geref history, compounding and sport

Geref received diagnostic approval in 1990 and pediatric idiopathic-GH-deficiency treatment approval in 1997. The manufacturer discontinued it in 2008; specific approvals were withdrawn in 2009. FDA’s later determination found the products had not been withdrawn for safety or effectiveness reasons. That is a historical product finding, not current approval for adult anti-aging or performance use.

No current FDA-approved marketed sermorelin product or current DailyMed label is identified. Compounded supply has a different footing from never-approved ingredients, while its regulatory position remains under FDA review. GHRH analogs including sermorelin are prohibited at all times by WADA.

Sources: [11], [16]

Direct adult research and regimen limits

GHRH physiology studies report augmented nocturnal GH release. This hormone-level finding does not establish improved muscle, fat, recovery or aging outcomes from sermorelin in healthy adults.

A six-week study in 11 older men reported greater nocturnal GH and selected strength/endurance improvements, without changes in IGF-I or DEXA muscle/fat measurements. A 14-day study in ten older men found dose-related GH and IGF-I responses, particularly at the higher exposure. These findings are biological/functional observations, not an established 2–3 kg muscle gain or general fat-loss effect.

The six-week study used 2 mg GHRH (1–29) nightly; the 14-day study tested 0.5 mg and 1 mg twice daily. These are research exposures rather than a universal 0.2–0.3 mg bedtime dose, workout schedule or cycle. Injectable study results do not validate an oral tablet, nasal spray or another formulation.

The small six-week study reported no significant adverse effects, but cannot measure rare risks, years of safety or comparative superiority. The acute GHRH/GHRP-6 combination study provides a mechanistic research rationale, not clinical proof for sermorelin/ipamorelin or a protective receptor-reset calendar.

Sources: [1], [17], [18], [20]

GHRH-class findings are not sermorelin efficacy trials

Tesamorelin shares the GHRH receptor but has its own evidence base:

GHRH-class context: tesamorelin results
Tesamorelin evidenceReported result
412-person HIV trial; 2 mg SC dailyAt 26 weeks, VAT −15.2% versus +5.0% placebo; p < 0.001.
Pooled Phase III trials; 806 participantsApproximately 15.4% VAT treatment effect at 26 weeks, sustained through 52 weeks; no clinically meaningful mean glucose difference.
12-month trial; 60 abdominally obese adults with reduced GHNet 19% VAT reduction and 37 mg/dL triglyceride reduction versus placebo.
Secondary analysis; 341 adults with HIV; 26 weeksIn responders versus placebo, truncal muscle density +1.56–4.86 Hounsfield units (all p < 0.005), lean muscle area +0.64–1.08 cm² across four groups.
Meta-analysis of five HIV RCTsLean body mass mean increase 1.42 kg; 95% CI 1.13–1.71, p< 0.001.

Those visceral-fat and lean-mass findings concern tesamorelin, not demonstrations that sermorelin improves muscle or fat in healthy adults. Selected functional changes in small sermorelin studies are a separate endpoint.

Sources: [3], [4], [5], [12], [13]

IGF-1, sleep and aging physiology

In seven men aged 65–78, a blunted GH response to testing improved after 100 micrograms IV GHRH-40 every two days for 12 days. A retrospective combination report in 14 men receiving testosterone plus sermorelin/GHRP-2/GHRP-6 for a mean 134 days found IGF-1 rose from 159.5 to 239.0 ng/mL, approximately 50% (p< 0.0001). Neither design isolates routine sermorelin wellness benefit.

IV GHRH sleep experiments found slow-wave sleep rose from 14.0% to 20.2% of total sleep time in seven healthy men—a 44% relative increase—and another young-men experiment reported almost a tenfold late-sleep increase. In older adults (mean age 69.3), awakenings decreased, but sleep/cortisol effects were smaller than in younger participants. Direct randomized subcutaneous-sermorelin sleep trials are not described.

“Somatopause” describes declining GH secretion beginning in early adulthood. Studies suggest contributions from reduced hypothalamic GHRH output and reduced pituitary responsiveness: some observed similar injected-GHRH responses by age, while others found a reduced response partly restored by repeated GHRH. These mechanisms do not establish longer life, fracture prevention, rejuvenated skin or a standard sleep/weight-results timetable.

Sources: [6], [7], [8], [9], [10], [14], [15]

References and further reading

This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .

  1. 10.1530/eje.0.1510561Direct adult research and regimen limitsCited in: Direct adult research and regimen limits
  2. pubmed.ncbi.nlm.nih.govIdentity, mechanism and pharmacokineticsCited in: Identity, mechanism and pharmacokinetics
  3. pubmed.ncbi.nlm.nih.govGHRH-class findings are not sermorelin efficacy trialsCited in: GHRH-class findings are not sermorelin efficacy trials
  4. pubmed.ncbi.nlm.nih.govGHRH-class findings are not sermorelin efficacy trialsCited in: GHRH-class findings are not sermorelin efficacy trials
  5. pubmed.ncbi.nlm.nih.govGHRH-class findings are not sermorelin efficacy trialsCited in: GHRH-class findings are not sermorelin efficacy trials
  6. pubmed.ncbi.nlm.nih.govIGF-1, sleep and aging physiologyCited in: IGF-1, sleep and aging physiology
  7. pubmed.ncbi.nlm.nih.govIGF-1, sleep and aging physiologyCited in: IGF-1, sleep and aging physiology
  8. pubmed.ncbi.nlm.nih.govIGF-1, sleep and aging physiologyCited in: IGF-1, sleep and aging physiology
  9. pubmed.ncbi.nlm.nih.govIGF-1, sleep and aging physiologyCited in: IGF-1, sleep and aging physiology
  10. pubmed.ncbi.nlm.nih.govIGF-1, sleep and aging physiologyCited in: IGF-1, sleep and aging physiology
  11. federalregister.govGeref history, compounding and sportCited in: Geref history, compounding and sport
  12. pubmed.ncbi.nlm.nih.govGHRH-class findings are not sermorelin efficacy trialsCited in: GHRH-class findings are not sermorelin efficacy trials
  13. pubmed.ncbi.nlm.nih.govGHRH-class findings are not sermorelin efficacy trialsCited in: GHRH-class findings are not sermorelin efficacy trials
  14. pubmed.ncbi.nlm.nih.govIGF-1, sleep and aging physiologyCited in: IGF-1, sleep and aging physiology
  15. pubmed.ncbi.nlm.nih.govIGF-1, sleep and aging physiologyCited in: IGF-1, sleep and aging physiology
  16. www.govinfo.gov — additional readingGeref history, compounding and sportCited in: Geref history, compounding and sport
  17. pubmed.ncbi.nlm.nih.gov — additional readingDirect adult research and regimen limitsCited in: Direct adult research and regimen limits
  18. pubmed.ncbi.nlm.nih.gov — additional readingDirect adult research and regimen limitsCited in: Direct adult research and regimen limits
  19. pubmed.ncbi.nlm.nih.gov — additional readingIdentity, mechanism and pharmacokineticsCited in: Identity, mechanism and pharmacokinetics
  20. pubmed.ncbi.nlm.nih.gov — additional readingDirect adult research and regimen limitsCited in: Direct adult research and regimen limits

Frequently Asked Questions About Sermorelin

Sermorelin stimulates the GHRH pathway; exogenous GH provides the hormone directly. This mechanism does not establish a general safety advantage.

The six-week older-men study found selected strength changes but no DEXA muscle or fat change. It does not establish a standard before-and-after timeline.

The small six-week study reported no significant adverse effects, but it cannot establish uncommon risks, long-term safety or comparative superiority.

Different studies used different research exposures. They do not establish a universal 0.2–0.3 mg dose, bedtime schedule or protective cycle.

Tesamorelin has specific current EGRIFTA labeling for HIV-associated lipodystrophy; Geref has a separate historical record. This is not a head-to-head efficacy or safety comparison.

The cited studies do not establish a general weight-loss indication or a standard amount of fat loss.

Historical Geref products and the cited research used injections. Their findings cannot verify the identity, availability or efficacy of a particular oral or nasal product.

Hormone responses and clinical changes are different endpoints. The studies do not establish a universal results calendar.

The 29-amino-acid GHRH analog stimulates a responsive pituitary; HGH supplies hormone directly. Feedback remains possible, but no head-to-head safety trial establishes a general advantage.

No. The strong visceral-fat studies summarized here used tesamorelin. Their receptor relationship does not make them sermorelin trials.

GH-axis stimulation can increase IGF-1. Small physiology studies and a 14-man testosterone/sermorelin/GHRP combination report support that biological activity, but do not isolate predictable wellness outcomes from sermorelin alone.

IV GHRH experiments found slow-wave-sleep changes, including 14.0% to 20.2% in seven men and smaller effects in older adults. These were not direct randomized subcutaneous-sermorelin sleep trials.

No marketed approved product is identified. Historical Geref diagnostic and pediatric approvals were discontinued; FDA later found withdrawal was not for safety or effectiveness. Compounding status remains a separate question.

A small sermorelin study found selected strength/endurance changes without DEXA muscle/fat change. The stronger lean-mass and muscle-area estimates discussed here come from tesamorelin, not sermorelin.

It is the age-related decline in GH secretion, with evidence implicating both less hypothalamic signaling and a less responsive pituitary. Some responsiveness can change with repeated GHRH; that does not establish anti-aging treatment benefit.

No universal home dose, bedtime rule, cycle or visible-results timetable is established by the differing small research regimens. The studies do not validate tablets or sprays.

No. Absence of significant adverse effects in a small six-week study cannot exclude rare risks, establish chronic safety or prove superiority to HGH.

Related Peptides

Continue exploring Sermorelin

Search all related references →

Our library review is ongoing. Read how we evaluate evidence or report a correction.

Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.